| Drug ID: | Drug11 |
|---|---|
| Drug Name: | Berberine |
| CID: | 2353 |
| DrugBank ID: | DB04115 |
| Modality: | Small Molecule |
| Groups: | experimental |
| US Approved: | NO |
| Other Approved: | NO |
| Identifier: | NCT02962245 |
| Molecular Formula: | C20H18NO4+ |
| Molecular Weight: | 336.4 g/mol |
| Isomeric SMILES: | COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC |
| Synonyms: | berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; Benzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium, 5,6-dihydro-9,10-dimethoxy- |
| Phase 0: | 2 |
| Phase 1: | 4 |
| Phase 2: | 15 |
| Phase 3: | 15 |
| Phase 4: | 21 |
| Description: | An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt90 | 2353 | Berberine | 7124 | TNF | Rattus norvegicus (Norway rat) | 25600690 | Berberine inhibits the reaction [mercuric chloride results in increased expression of TNF protein] |
| dt91 | 2353 | Berberine | 7150 | TOP1 | Homo sapiens (human) | 23747414 | Berberine results in decreased activity of TOP1 protein |
| dt92 | 2353 | Berberine | 7153 | TOP2A | Homo sapiens (human) | 23747414 | TOP2A protein affects the susceptibility to berberine|top2a protein affects the reaction [berberine results in increased expression of H2AX protein modified form] |
| dt93 | 2353 | Berberine | 7157 | TP53 | Homo sapiens (human) | 26712469 | Berberine results in increased phosphorylation of and results in increased acetylation of TP53 protein|[berberine co-treated with niacinamide] results in increased expression of and results in increased acetylation of TP53 protein |
| dt94 | 2353 | Berberine | 7157 | TP53 | Homo sapiens (human) | 20656010 | Berberine results in increased expression of TP53 mrna|berberine results in increased expression of TP53 protein |
| dt95 | 2353 | Berberine | 7186 | TRAF2 | Mus musculus (house mouse) | 30240693 | Berberine inhibits the reaction [[lipopolysaccharide, escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]|berberine inhibits the reaction [[lipopolysaccharide, escherichia coli O111 B4 co-treated with TNF |
| dt96 | 2353 | Berberine | 6737 | TRIM21 | Homo sapiens (human) | 36822301 | Berberine promotes the reaction [IGF2BP3 protein binds to TRIM21 protein] |
| dt97 | 2353 | Berberine | 100131187 | TSTD1 | Homo sapiens (human) | 27311644 | Berberine results in increased expression of TSTD1 mRNA |
| dt98 | 2353 | Berberine | 7319 | UBE2A | Homo sapiens (human) | 27311644 | Berberine results in decreased expression of UBE2A mRNA |
| dt99 | 2353 | Berberine | 7320 | UBE2B | Homo sapiens (human) | 27311644 | Berberine results in decreased expression of UBE2B mRNA |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT02962245 | Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis | PHASE4 | WITHDRAWN | Xijing Hospital of Digestive Diseases | Ulcerative Colitis | DRUG: berberine|DRUG: regular treatment | Details |
| ChiCTR2400083224 | A clinical trial to evaluate the relationship between nitric oxide content in type 3 natural lymphocytes and severity of enteritis and response to drug intervention in patients with inflammatory bowel disease | Not Available | Not Recruiting | Peking University Third Hospital | Inflammatory Bowel Disease | Trial group:Berberine hydrochloride tablets mesa… | Details |
| NCT02365480 | Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission | PHASE1 | COMPLETED | National Cancer Institute (NCI) | Ulcerative Colitis | DRUG: Berberine Chloride|OTHER: Laboratory Biomar… | Details |
| NCT04985968 | The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis | PHASE3 | TERMINATED | InDex Pharmaceuticals | Ulcerative Colitis | DRUG: Cobitolimod 250 mg|DRUG: Cobitolimod 500 mg… | Details |
| NCT06681181 | A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants | PHASE1 | RECRUITING | GlaxoSmithKline | Colitis, Ulcerative | DRUG: GSK4528287|DRUG: Placebo | Details |
| NCT05992142 | ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA | PHASE4 | COMPLETED | Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | Ulcerative Colitis | DRUG: 5-ASA | Details |
| NCT00787202 | A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis. | PHASE2 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: CP- 690 550|DRUG: CP- 690 550|DRUG: CP- 690… | Details |
| NCT06321887 | EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD | PHASE3 | RECRUITING | Liverpool University Hospitals NHS Foundation Trust | Inflammatory Bowel Disease|Iron Deficiency Anemia | DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… | Details |
| NCT00207688 | A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients | None | COMPLETED | Janssen Research & Development, LLC | Ulcerative Colitis | DRUG: Infliximab 5 mg/kg|DRUG: Infliximab 10 mg/k… | Details |
| NCT04677179 | A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) | PHASE2 | TERMINATED | Nektar Therapeutics | Colitis, Ulcerative | DRUG: LY3471851|DRUG: Placebo | Details |
| NCT02958865 | Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis | PHASE2 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: PF-06651600 or Placebo|DRUG: PF-06700841 or… | Details |
| NCT03943550 | Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC) | PHASE1 | TERMINATED | Hoffmann-La Roche | Ulcerative Colitis | DRUG: RO7049665|DRUG: Placebo | Details |
| NCT02840721 | Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis. | PHASE2 | COMPLETED | Telavant, Inc. | Colitis, Ulcerative | DRUG: PF-06480605 | Details |
| NCT04133194 | Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis | PHASE4 | RECRUITING | Flemming Bendtsen | Ulcerative Colitis | DRUG: Mesalazine|DRUG: Mesalazine | Details |
| NCT01465763 | A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis | PHASE3 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: tofacitinib|DRUG: Placebo | Details |
| NCT06636656 | A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis | PHASE2 | RECRUITING | Boehringer Ingelheim | Ulcerative Colitis | DRUG: BI 3032950 intravenous (Part A)|DRUG: BI 30… | Details |
| NCT04996797 | A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) | PHASE2 | ACTIVE_NOT_RECRUITING | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Ulcerative Colitis | DRUG: Tulisokibart|DEVICE: Companion Diagnostic (… | Details |
| NCT01458951 | A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis | PHASE3 | COMPLETED | Pfizer | Ulcerative Colitis | DRUG: tofacitinib|DRUG: Placebo | Details |
| NCT04499495 | Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea | None | COMPLETED | Ferring Pharmaceuticals | Ulcerative Colitis | OTHER: PENTASA (mesalamine/ 5-Aminosalicylic acid… | Details |
| NCT01959282 | A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis | PHASE2 | COMPLETED | Janssen Research & Development, LLC | Colitis, Ulcerative | DRUG: Placebo|DRUG: JNJ-54781532 25 mg once daily… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S06 | Anti-fibrosis | fibrosis; tissue remodelling | GS-5745; STNM01 | Tissue remodelling and destruction in patients with IBD is … | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
Berberine mitigates colitis-associated neuroinflammation and anxiety through mo…
PMID: 40569370
Year: 2025
Relationship Type:
Treatment
Score: 9.5
Inflammatory bowel disease (IBD) is linked to psychiatric issues like anxiety and depression. Berberine (BER), a natural compound with anti-inflammat…
A novel pH-responsive berberine-loaded attapulgite microsphere for IBD therapy …
PMID: 40381667
Year: 2025
Relationship Type:
Treatment
Score: 9.5
Inflammatory bowel disease (IBD) is an idiopathic, lifelong, and devastating chronic inflammatory disease of the gastrointestinal tract. Berberine, a…
Epiberberine ameliorates ulcerative colitis by regulating bile acids hepatoente…
PMID: 40334429
Year: 2025
Relationship Type:
Treatment
Score: 9.5
BACKGROUND: Ulcerative colitis (UC) is a chronic inflammatory bowel disease, the development of which is accompanied by dysregulation of bile acid me…
Absolute Quantitative Metagenomic Analysis Provides More Accurate Insights for …
PMID: 40149936
Year: 2025
Relationship Type:
Association
Score: 9.5
Current gut microbiota studies often rely on relative quantitative sequencing. However, under certain circumstances, while the relative quantitative …
Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Infl…
PMID: 40006007
Year: 2025
Relationship Type:
Treatment
Score: 9.5
Berberine is a promising agent for modulating the intestinal microbiota, playing a crucial role in human health homeostasis. This natural compound pr…
Berberine disrupts the high-affinity iron transport system to reverse the fluco…
PMID: 39929396
Year: 2025
Relationship Type:
Treatment
Score: 9.5
Invasive fungal infection is usually caused by Candida albicans infection, which has a high incidence rate and mortality in critically ill patients. …
Therapeutic potential and underlying mechanisms of phytoconstituents: emphasizi…
PMID: 39878817
Year: 2025
Relationship Type:
Treatment
Score: 9.5
Ulcerative colitis is a long-term inflammatory colon illness that significantly affects patients quality of life. Traditional medicines and therapies…
Berberine‑calcium alginate-coated macrophage membrane-derived nanovesicles for …
PMID: 39755317
Year: 2025
Relationship Type:
Treatment
Score: 9.5
In this study, we developed calcium alginate-coated nanovesicles derived from macrophage membranes loaded with berberine (Ber@MVs-CA) for the oral tr…
Comprehensive plasma metabolomics analysis of berberine treatment in ulcerative…
PMID: 39722837
Year: 2024
Relationship Type:
Treatment
Score: 9.5
BACKGROUND: Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) influenced by multiple factors. Berberine, an isoquinoline alkaloid…
Berberine ameliorates dextran sulfate sodium -induced colitis through tuft cell…
PMID: 39617924
Year: 2024
Relationship Type:
Treatment
Score: 9.5
BACKGROUND: Inflammatory bowel disease (IBD), a persistent gastrointestinal disease, is featured with impaired gut immunity. Previous studies have de…
Berberine attenuates TNBS-induced colitis in mice by improving the intestinal m…
PMID: 39268532
Year: 2024
Relationship Type:
Treatment
Score: 9.5
OBJECTIVE: To investigate the effects of berberine (BBR) as a treatment on intestinal microecological alterations and enteritis in mice produced by T…
Berberine alleviates inflammation and suppresses PLA2-COX-2-PGE2-EP2 pathway th…
PMID: 38154262
Year: 2024
Relationship Type:
Mechanism
Score: 9.5
Berberine, isolated from Coptis chinensis and Phellodendron amurense, can attenuate colonic injury and modulate gut microbiota disorders in ulcerativ…
Thinking About Berberine
PMID: 38144162
Year: 2023
Relationship Type:
Treatment
Score: 9.5
The alkaloid berberine is a constituent of several medicinal herbs with centuries of use. Emerging research is documenting many effective clinical ap…
Cationic fructan-based pH and intestinal flora dual stimulation nanoparticle wi…
PMID: 37979767
Year: 2024
Relationship Type:
Treatment
Score: 9.5
Inflammatory bowel disease (IBD) can cause intestinal microbial imbalance and aggravate intestinal inflammation. Mixed fructan is more easily ferment…
Coptis chinensis and Berberine Ameliorate Chronic Ulcerative Colitis: An Integr…
PMID: 37930330
Year: 2023
Relationship Type:
Treatment
Score: 9.5
Coptis chinensis Franch (RC), has historically been used for the treatment of "Xiao Ke" and "Xia Li" symptoms in China. "Xia Li" is characterized by …
Synergistic effect of berberine hydrochloride and dehydrocostus lactone in the …
PMID: 37820424
Year: 2023
Relationship Type:
Treatment
Score: 9.5
Ulcerative colitis (UC) is a difficult-to-cure and recurrent inflammatory bowel disease, and it is difficult to maintain long-term results with a sin…
Combination of Coptis chinensis polysaccharides and berberine ameliorates ulcer…
PMID: 37595814
Year: 2024
Relationship Type:
Treatment
Score: 9.5
ETHNOPHARMACOLOGICAL RELEVANCE: Coptis chinensis Franch. polysaccharide (CCP) and berberine (BBR) are the primary active components of Coptis chinens…
Rhubarb polysaccharide and berberine co-assembled nanoparticles ameliorate ulce…
PMID: 37408766
Year: 2023
Relationship Type:
Treatment
Score: 9.5
Introduction: Inflammatory bowel disease (IBD) affects about 7 million people globally, which is a chronic inflammatory condition of the gastrointest…
pH-sensitive HPMCP-chitosan nanoparticles containing 5-aminosalicylic acid and …
PMID: 37302632
Year: 2023
Relationship Type:
Treatment
Score: 9.5
Ulcerative colitis (UC) with continuous and extensive inflammation is limited to the colon mucosa and can lead to abdominal pain, diarrhea, and recta…
[Therapeutic effect of ursodeoxycholic acid-berberine supramolecular nanopartic…
PMID: 37282934
Year: 2023
Relationship Type:
Treatment
Score: 9.5
Ulcerative colitis(UC) is a recurrent, intractable inflammatory bowel disease. Coptidis Rhizoma and Bovis Calculus, serving as heat-clearing and toxi…